Show simple item record

dc.contributor.authorHeffernan, C B
dc.contributor.authorO'Neill, J P
dc.contributor.authorTimon, C
dc.date.accessioned2012-02-01T10:40:17Z
dc.date.available2012-02-01T10:40:17Z
dc.date.issued2012-02-01T10:40:17Z
dc.identifier.citationJ Laryngol Otol. 2010 Sep;124(9):941-4. Epub 2010 Jun 2.en_GB
dc.identifier.issn1748-5460 (Electronic)en_GB
dc.identifier.issn0022-2151 (Linking)en_GB
dc.identifier.pmid20519038en_GB
dc.identifier.doi10.1017/S0022215110001179en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207756
dc.description.abstractThere is considerable debate within the literature about the significance of human papilloma virus in head and neck squamous cell carcinoma, and its potential influence on the prevention, diagnosis, grading, treatment and prognosis of these cancers. Cigarette smoking and alcohol consumption have traditionally been cited as the main risk factors for head and neck cancers. However, human papilloma virus, normally associated with cervical and other genital carcinomas, has emerged as a possible key aetiological factor in head and neck squamous cell carcinoma, especially oropharyngeal cancers. These cancers pose a significant financial burden on health resources and are increasing in incidence. The recent introduction of vaccines targeted against human papilloma virus types 16 and 18, to prevent cervical cancer, has highlighted the need for ongoing research into the importance of human papilloma virus in head and neck squamous cell carcinoma.
dc.language.isoengen_GB
dc.subject.meshAdolescenten_GB
dc.subject.meshAdulten_GB
dc.subject.meshCarcinoma, Squamous Cell/epidemiology/*virologyen_GB
dc.subject.meshChilden_GB
dc.subject.meshFemaleen_GB
dc.subject.mesh*Human papillomavirus 16/genetics/immunologyen_GB
dc.subject.mesh*Human papillomavirus 18/genetics/immunologyen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMucous Membrane/virologyen_GB
dc.subject.meshOropharyngeal Neoplasms/epidemiology/*virologyen_GB
dc.subject.meshPapillomavirus Infections/complications/epidemiology/*prevention & controlen_GB
dc.subject.mesh*Papillomavirus Vaccines/immunologyen_GB
dc.subject.meshPrevalenceen_GB
dc.subject.meshRisk Factorsen_GB
dc.subject.meshSexual Behavioren_GB
dc.subject.meshSexually Transmitted Diseases, Viral/complications/epidemiologyen_GB
dc.subject.meshUterine Cervical Neoplasms/prevention & control/virologyen_GB
dc.titleOncogenic impact of human papilloma virus in head and neck cancer.en_GB
dc.contributor.departmentThe Royal Victoria Eye and Ear Hospital, Adelaide Road, Dublin, Ireland., Heffernan_colleen@hotmail.comen_GB
dc.identifier.journalThe Journal of laryngology and otologyen_GB
dc.description.provinceLeinster
html.description.abstractThere is considerable debate within the literature about the significance of human papilloma virus in head and neck squamous cell carcinoma, and its potential influence on the prevention, diagnosis, grading, treatment and prognosis of these cancers. Cigarette smoking and alcohol consumption have traditionally been cited as the main risk factors for head and neck cancers. However, human papilloma virus, normally associated with cervical and other genital carcinomas, has emerged as a possible key aetiological factor in head and neck squamous cell carcinoma, especially oropharyngeal cancers. These cancers pose a significant financial burden on health resources and are increasing in incidence. The recent introduction of vaccines targeted against human papilloma virus types 16 and 18, to prevent cervical cancer, has highlighted the need for ongoing research into the importance of human papilloma virus in head and neck squamous cell carcinoma.


This item appears in the following Collection(s)

Show simple item record